EurekAlert! · Dec 2023
UCLA/Duke-NUS research on RNA splicing and cardiomyocyte maturation included Forcyte Biotechnologies as a collaborating institution, reinforcing the company’s relevance in cardiac mechanobiology research.
Discover drugs that control how much cells "squeeze" to treat disease
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Forcyte Biotechnologies is a Los Angeles-based, seed-stage biotechnology company that uses mechanobiology to discover drugs by measuring how cells contract/squeeze rather than relying only on conventional biochemical readouts. Its flagship FLECS platform quantifies single-cell mechanical function in high-throughput 384-well format and underpins both external pharma partnerships and an internal mechano-therapeutic pipeline.
Primary product
FLECS (Force-Linked ECM Cytometry) mechanomics platform
Founded
2017
Headquarters
1100 Glendon Ave Fl 17, Los Angeles, CA 90024, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Mechanobiology drug discovery / biotechnology research
Offices
570 Westwood Plaza Building 114, Los Angeles, CA 90095, United States
11957 Darlington Avenue, Los Angeles, CA 90049, United States
11957 Darlington Ave Ste 202, Los Angeles, CA 90049, United States
Business model
drug discovery partnerships
internal therapeutics pipeline
mechanobiology screening platform
Funding
Stage
Seed
Total raised
$5.7M
Latest round
Seed VC-II · Jun 2022
Jun 2022 · Y Combinator
Apr 2021
Feb 2021
Jan 2019
People & investors
Leadership
CEO & Co-Founder
Co-Founder and Board Member
Co-founder & Scientific Advisor
Interim Head of Corp Development
Interim Dir Med Chem
Interim Head of Biology
Sr. Scientist
Work & culture
Mission-driven, builder-oriented startup culture centered on function-first biology, mechanobiology, and translational drug discovery; hiring language emphasizes big ideas, energy, and a love for building.
Visa sponsorship
Limited
Compensation
A 2022 hiring post advertised a competitive salary, stock options, full health benefits, and covered parking. Public DOL/PERM data shows at least one 2021 filing for a Chemical Engineer at $91,000 base salary, indicating some U.S. work authorization sponsorship activity, but no explicit current sponsorship policy was published.
Benefits
competitive salary
stock options
full health benefits
parking covered
Product & market
Differentiators
- —measures cellular force/contractility directly
- —single-cell, high-throughput mechanobiology readout
- —automation-ready 384-well format
- —mechanics-first phenotypic screening
- —maps genomics and pharmacology to mechanical cell function
- —UCLA-originated and licensed platform
- —screens primary human cells at scale
Technology
FLECS platform
bioMEMS
micropatterned elastomer films
384-well automation
computer vision-based force quantification
single-cell contractility screening
primary human cell assays
drug library screening
RNAi screening
CRISPR screening
mechanomics database
Scale & contact
Estimated revenue
$1M-$10M
Latest news
Mirage News · Oct 2023
A UCLA-led study on stem-cell-derived heart muscle maturation listed Forcyte Biotechnologies among collaborators, highlighting the company’s mechanobiology research footprint.
Labiotech · Sep 2023
Profiled Forcyte Biotechnologies as a Los Angeles biotech company building a mechanobiology dataset with the FLECS platform and a preclinical pipeline for fibrosis, asthma, and overactive bladder.
Business Wire · Jun 2022
Announced new funding from Y Combinator, Milestone View, Pioneer Fund, Acequia Capital, Jude Gomila, and others; total raised exceeded $5.7M.
Jobs and careers at Forcyte Biotechnologies
0 jobs at Forcyte Biotechnologies
No open positions
Check back later for new openings